Amedica Corporation (AMDA) Upgraded to Hold by ValuEngine

ValuEngine upgraded shares of Amedica Corporation (NASDAQ:AMDA) from a sell rating to a hold rating in a report released on Friday morning.

Separately, Maxim Group cut shares of Amedica Corporation from a buy rating to a hold rating in a research report on Monday, September 25th.

Amedica Corporation (NASDAQ AMDA) traded up $3.35 during mid-day trading on Friday, hitting $3.66. 910,700 shares of the stock were exchanged, compared to its average volume of 125,382. Amedica Corporation has a one year low of $3.12 and a one year high of $13.08.

TRADEMARK VIOLATION NOTICE: This report was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this report on another site, it was copied illegally and reposted in violation of United States & international trademark & copyright laws. The correct version of this report can be viewed at

An institutional investor recently raised its position in Amedica Corporation stock. Vanguard Group Inc. boosted its holdings in Amedica Corporation (NASDAQ:AMDA) by 7.1% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 595,866 shares of the medical equipment provider’s stock after acquiring an additional 39,603 shares during the quarter. Vanguard Group Inc. owned 2.26% of Amedica Corporation worth $226,000 at the end of the most recent quarter. 4.90% of the stock is currently owned by hedge funds and other institutional investors.

Amedica Corporation Company Profile

Amedica Corporation is a commercial biomaterial company. The Company is a vertically integrated silicon nitride orthopedic medical device manufacturer. It is focused on using its silicon nitride ceramic technology platform to develop, manufacture and sell a range of medical devices. It is also engaged in developing wear- and corrosion-resistant implant components for hip and knee arthroplasty.

Receive News & Ratings for Amedica Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedica Corporation and related companies with's FREE daily email newsletter.

Leave a Reply